Form 4: Atara Biotherapeutics Director Acquires 7,828 Restricted Stock Units Following Reverse Stock Split

Atara Biotherapeutics Director Maria Grazia Roncarolo reported the acquisition of 7,828 restricted stock units, increasing her beneficial ownership to 17,368 shares, following a recent 1:25 reverse stock split.

Summary

• Maria Grazia Roncarolo, a Director of Atara Biotherapeutics, Inc. (ATRA), acquired 7,828 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 10, 2025.
• The RSUs were acquired at a price of $0, which is typical for equity grants.
• Following this transaction, Ms. Roncarolo's beneficial ownership stands at 17,368 shares.
• The 17,368 shares reflect the impact of a 1:25 reverse stock split implemented by Atara Biotherapeutics on June 20, 2024.
• These restricted stock units are subject to vesting on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent on Ms. Roncarolo's continuous service.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally viewed positively as it aligns insider interests with shareholder value, though it's an equity grant rather than a direct cash purchase. The mention of a 1:25 reverse stock split, while a corporate action, can sometimes be perceived as a measure taken by companies with a low stock price.

Positives

• Director Maria Grazia Roncarolo acquired 7,828 restricted stock units, indicating continued alignment of interests with shareholders through equity compensation.

Future Outlook

The acquired restricted stock units are scheduled to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent upon the reporting person's continuous service.

Management Comments

• The acquisition of restricted stock units by a director aligns management's interests with long-term shareholder value.

Industry Context

This filing is a standard disclosure of insider stock ownership changes, common across all publicly traded industries, including biotechnology. The reverse stock split mentioned is a corporate action that can occur in various sectors, often to increase share price and meet listing requirements.

Related Party Transactions

• The acquisition of 7,828 restricted stock units by Director Maria Grazia Roncarolo represents an equity compensation grant, a common form of related party transaction between a company and its executives/directors.

Stakeholder Impact

• Shareholders: The acquisition of restricted stock units by a director aligns management's long-term interests with those of shareholders.

Next Steps

• Vesting of 7,828 restricted stock units on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Form 4, insider transaction, beneficial ownership, restricted stock units, RSU, director, equity compensation, reverse stock split